Efficacy and safety of adjunctive bitopertin (5 and 10 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics - Results from the phase III DayLyte study

Schizophrenia Research

Volumn 158, Issue 1-3, 2014, Pages

  Arango, Celso ^a   Nasrallah, Henry ^b   Lawrie, Stephen ^c   Lohmann, Tania Ochi ^d   Zhu, Jon Luca ^e   Garibaldi, George ^d   Wang, Alice ^f   Bugarski Kirola, Dragana ^d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e Roche Product Development in Asia Pacific   (China)

^f Roche (China) Holding Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BITOPERTIN; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H RELATED 1; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERSONAL AND SOCIAL PERFORMANCE SCORE; PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 84906812178     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.07.038     Document Type: Article

References (0)